NCT06602739View on ClinicalTrials.gov

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 19, 2024

Primary Completion Date

April 23, 2025

Study Completion Date

August 2, 2025

Conditions

Allergic Conjunctivitis

Interventions

DRUG

REGN5713

Administered per protocol

DRUG

REGN5715

Administered per protocol

DRUG

Placebo

Administered per protocol

Trial Locations (3)

01810

Andover Eye Associates, Andover

K7L 2V7

Kingston Health Sciences Centre, Kingston

G1V 4W2

Clinique de Specialisee en Allergie de la Capitale, Québec

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06602739 - A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy | Biotech Hunter | Biotech Hunter